Ignota Labs is an innovative startup that aims to revolutionize drug discovery by utilizing AI to address toxicity issues in abandoned drug candidates. The company recently raised $6.9 million to refine these drugs for further clinical trials. CEO Sam Windsor highlights that their method can complete the same development that traditionally costs over $10 million in less than two years and for under $1 million. Ignota Labs uniquely targets drugs that were close to success but failed due to safety concerns, an area largely overlooked by other companies in the AI drug discovery space.
"Traditional drug discovery might cost over $10 million and take seven to eight years just to reach clinical trials. Our approach can achieve the same in less than two years and for under $1 million."
"Safety is seen as sort of like a hurdle you have to get over rather than the exciting end goal in its own right. People with the stereotypical 'let's go change the world' mindset aren't the sort who end up in safety science."
Collection
[
|
...
]